SEQUENCE LISTING

<110> Perlan Therapeutics
Fang, Fang

<120> Identifying Ligands of Target Proteins With Target Complementary Library Technology (TCLT)

<130> 014357-0278746

<140> 09/674,014
<141> 2001-02-08

<150> WO PCT/US99/06537
<151> 1999-04-19

<150> US 60/083,046
<151> 1998-04-24

<160> 27

<170> PatentIn Ver. 2.0

<210> 1
<211> 15
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sense strand of target gene

Boarded.

<400> 1

cuuuguuucu uuuuu 15

<210> 2
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: sense strand of target gene encoded peptide

<400> 2

Leu Val Leu Phe
1

<210> 3
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense peptide encoded by anti-sense strand

<400> 3

Lys Lys Asn Lys
1

<210> 4
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense strand

<400> 4

aaaaagaaca ag 12

<210> 5
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense peptide encoded by anti-sense strand

<400> 5

Glu Gln Glu Lys
1

<210> 6
<211> 12
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: anti-sense strand

<400> 6

gaacaagaaa aa 12

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic degenerate BglI deoxyoligonucleotide fragment

<220>
<221> modified_base
<222> (1)..(20)
<223> phosphoramidite nucleotides

<400> 7

ctgtcagggc ccgaggggct 20

<210> 8
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: synthetic degenerate BglI deoxyoligonucleotide fragment

<220>
<221> modified_base
<222> (1)..(22)
<223> phosphoramidite nucleotides

<400> 8

ggggccgctg cggcctgtca gg 22

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ICAM-1 domain D1 residues 1-5 peptide target for human rhinovirus (HRV)

<400> 9

Gln Thr Ser Val Ser
1 5

<210> 10
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ICAM-1 domain D1 residues 24-29 peptide target for human rhinovirus (HRV)

<400> 10

Ser Cys Asp Gln Pro Lys
1 5

<210> 11
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: ICAM-1 domain D1 residues 40-49 peptide target for human rhinovirus (HRV)

<400> 11

Lys Glu Leu Leu Leu Pro Gly Asn Asn Arg
1 5 10

<210> 12
<211> 8
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: ICAM-1 domain D1 residues 70-77 peptide target for human rhinovirus (HRV)

<400> 12

Pro Asp Gly Gln Ser Thr Ala Lys
1 5

<210> 13
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H1 family heavy chain

<220>
<221> MOD_RES
<222> (3)

<223> Xaa = Arg or Gln

<220>
<221> MOD_RES
<222> (6)
<223> Xaa = Pro, His or Thr

<220>
<221> MOD_RES
<222> (7)
<223> Xaa = Gly or Ala

<220>
<221> MOD_RES
<222> (8)
<223> Xaa = Lys or Gln

<220>
<221> MOD_RES
<222> (9)
<223> Xaa = Gly, Glu, Arg or Ala

<220>
<221> MOD_RES
<222> (11)
<223> Xaa = Glu or Gly

B1

<220>
<221> MOD_RES
<222> (13)
<223> Xaa = Met or Ile

<400> 13

Trp Val Xaa Gln Ala Xaa Xaa Xaa Xaa Leu Xaa Trp Xaa Gly
1 5 10

<210> 14
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H2 family heavy chain

<400> 14

Trp Ile Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Ala
1 5 10

<210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H3 family heavy chain

<220>
<221> MOD_RES
<222> (2)
<223> Xaa = Val or Ile

<220>
<221> MOD_RES
<222> (3)
<223> Xaa = Arg or His

<220>
<221> MOD_RES
<222> (6)
<223> Xaa = Pro or Gln

<220>
<221> MOD_RES
<222> (10)
<223> Xaa = Leu or Pro

<220>
<221> MOD_RES
<222> (11)
<223> Xaa = Glu or Val

<220>
<221> MOD_RES
<222> (12)
<223> Xaa = Trp, Tyr or Leu

<220>
<221> MOD_RES
<222> (14)
<223> Xaa = Ser, Ala or Gly

<400> 15

Trp Xaa Xaa Gln Ala Xaa Gly Lys Gly Xaa Xaa Xaa Val Xaa
1 5 10

<210> 16
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H4 family heavy chain

<220>
<221> MOD_RES
<222> (2)
<223> Xaa = Ile or Val

<400> 16

Trp Xaa Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile Gly
1 5 10

B1

<210> 17
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H5 family heavy chain

<220>
<221> MOD_RES
<222> (9)
<223> Xaa = Gly or Glu

<400> 17

Trp Val Arg Gln Met Pro Gly Lys Xaa Leu Glu Trp Met Gly
1 5 10

<210> 18
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: general sequence of framework 2 (FR2) region from V-H6 family heavy chain

<400> 18

Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly
1 5 10

<210> 19
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: framework 2 (FR2) region from V-L kappa light chain

<220>
<221> MOD_RES
<222> (8)
<223> Xaa = Gln or Lys

<220>
<221> MOD_RES
<222> (9)
<223> Xaa = Pro, Ser or Ala

<400> 19

Trp Tyr Gln Gln Lys Pro Gly Xaa Xaa Pro Lys Leu Leu Ile Tyr
1 5 10 15

<210> 20
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: IgE-blocking peptide 1 binds to FR2 in V-H5

<220>
<221> MOD_RES
<222> (10)
<223> Xaa = Gln or Asp

<400> 20

Pro Asp Ala Leu His Gly Pro Phe Ala Xaa Leu Pro His Pro
1 5 10

<210> 21
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: IgE-blocking peptide 2 binds to FR2 in V-H3, V-H4 and V-H6

<220>
<221> MOD_RES
<222> (5)
<223> Xaa = Gly or Arg

<220>
<221> MOD_RES
<222> (10)
<223> Xaa = Gln or Asp

<400> 21

Pro Asp Ala Leu Xaa Gly Pro Phe Ala Xaa Leu Pro Asn Pro
1 5 10

<210> 22
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: IgE-blocking peptide 3 binds to FR2 in V-L kappa

<400> 22

Pro Val Leu Leu Phe Arg Pro Leu Arg Gly Phe Glu Glu Asp Ile
1 5 10 15

<210> 23
<211> 15
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer No.1

<220>
<221> modified_base
<222> (10)..(15)
<223> n = a, t, c or g

<400> 23

gacgtggccn nnnnn 15

<210> 24
<211> 13
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer No. 2

<400> 24

ggccgacgtg gcc 13

<210> 25
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer No. 1

<220>
<221> modified_base
<222> (13)..(18)
<223> n = a, t, c or g

<400> 25

gacgtggcct gtnnnnnn 18

<210> 26
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer No. 2

<400> 26

ggccgacgtg gcctgt 16

<210> 27
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 27

ccctcatagt taagcgtaac g 21